Northwest Biotherapeutics Closes Acquisition of Advent BioServices
Northwest Biotherapeutics has completed its acquisition of Advent BioServices, making Advent a wholly owned subsidiary, announced in a press release. The company stated that the acquisition will enable operational efficiencies, scale-up of manufacturing, and integration of technologies and intellectual property from both organizations.
As part of the transaction, Northwest Biotherapeutics will acquire all of Advent's fixed assets, including cryostorage and equipment, as well as intellectual property and other intangibles. The company will not issue new shares for the acquisition; instead, 19 million previously issued securities will revert to Northwest Biotherapeutics.
The payment terms include £1.4 million and the net accounts payable due to Advent, to be paid in installments over two years. Installment payments will begin 90 days after the October closing, with potential acceleration following regulatory approval of the DCVax-L product. The integration will also consolidate operations at the Sawston, UK facility and support capacity expansion in the United States.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 19 Knit Health raises $35 million to roll out its healthcare world model Nov 19 Banner Health invests in Layer Health and moves its clinical registries onto its AI platform Nov 19 Half of Koreans who changed medication on AI advice had side effects, survey finds Nov 19 Isomorphic Labs and MSD team up to design cancer drugs with AI Nov 19 Boltz raises $110 million to build AI models for drug designMore from Funding
Nov 20 hackajob raises $10 million to expand Archer, its AI recruiting agent Nov 20 Protesters rally against Anthropic in New York and San Francisco on its stock market debut Nov 19 Anthropic's IPO could channel about $156 billion to charity, TechCrunch estimates Nov 19 Sierra reportedly in talks to raise at a $30 billion valuation Nov 19 Everful raises $48.5 million to build AI infrastructure for global commerceAI Funding Brief
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Araceli Biosciences Adds Investor to $4.5 Million Round
Remedy Robotics raises $62M Series B for AI-enabled endovascular robot
Agility Robotics Expects $465 Million Raise as SPAC Merger Nears Close
Formation Bio Forms $600 Million Drug Development Fund
Wolters Kluwer to buy AI clinical decision support company AgileMD for up to $100 million
Daily AI Brief: the AI news that matters, in your inbox.